病例报告:BALB/cJ小鼠对环孢素A治疗的不良反应。

IF 1.3 4区 农林科学 Q2 VETERINARY SCIENCES
Laboratory Animals Pub Date : 2023-12-01 Epub Date: 2023-07-03 DOI:10.1177/00236772231177857
Vaughn Ticar, Allison Tschirley, Michelle Wilson, Anene du Plessis, Merilyn Hibma
{"title":"病例报告:BALB/cJ小鼠对环孢素A治疗的不良反应。","authors":"Vaughn Ticar, Allison Tschirley, Michelle Wilson, Anene du Plessis, Merilyn Hibma","doi":"10.1177/00236772231177857","DOIUrl":null,"url":null,"abstract":"<p><p>Cyclosporin A (CsA) is an immunosuppressive drug that has been widely used in mice at a range of doses from 10 to 200 mg/kg. Our group carried out an experiment in 2016 where we delivered 75 mg/kg CsA (Neoral<sup>TM</sup>) to BALB/cJ mice by oral gavage to enable wart formation in mice, which was moderately well-tolerated. We recently commenced another study using the same dose and route of delivery of CsA in BALB/cJ mice in order to immune suppress mice to make them susceptible for mouse papillomavirus infection. We highlight in this case report that in contrast to our earlier study, we observed almost immediate unexpected toxicity and had to terminate the recent experiment after only five days of treatment. Seven to eight-week-old female BALB/cJ mice were treated with 75 mg/kg of CsA by oral gavage daily for five days before treatment was stopped due to body weight loss and mice becoming moribund. The probability of survival of the mice following CsA treatment was 80% in this study, compared with 98% in our 2016 study. Mice showed signs of probable acute kidney injury, which was reversible following withdrawal of CsA. Although it is unclear why the clinical response to CsA in BALB/cJ mice differed markedly between the two experiments, this case report highlights the risk of CsA to mouse welfare. CD3 depletion has been used rather than CsA treatment in other studies and should be considered as an alternative to CsA treatment as it is immune-selective, and may be more effective at enabling wart formation in mice.</p>","PeriodicalId":18013,"journal":{"name":"Laboratory Animals","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case report: An adverse response to cyclosporin A treatment in BALB/cJ mice.\",\"authors\":\"Vaughn Ticar, Allison Tschirley, Michelle Wilson, Anene du Plessis, Merilyn Hibma\",\"doi\":\"10.1177/00236772231177857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cyclosporin A (CsA) is an immunosuppressive drug that has been widely used in mice at a range of doses from 10 to 200 mg/kg. Our group carried out an experiment in 2016 where we delivered 75 mg/kg CsA (Neoral<sup>TM</sup>) to BALB/cJ mice by oral gavage to enable wart formation in mice, which was moderately well-tolerated. We recently commenced another study using the same dose and route of delivery of CsA in BALB/cJ mice in order to immune suppress mice to make them susceptible for mouse papillomavirus infection. We highlight in this case report that in contrast to our earlier study, we observed almost immediate unexpected toxicity and had to terminate the recent experiment after only five days of treatment. Seven to eight-week-old female BALB/cJ mice were treated with 75 mg/kg of CsA by oral gavage daily for five days before treatment was stopped due to body weight loss and mice becoming moribund. The probability of survival of the mice following CsA treatment was 80% in this study, compared with 98% in our 2016 study. Mice showed signs of probable acute kidney injury, which was reversible following withdrawal of CsA. Although it is unclear why the clinical response to CsA in BALB/cJ mice differed markedly between the two experiments, this case report highlights the risk of CsA to mouse welfare. CD3 depletion has been used rather than CsA treatment in other studies and should be considered as an alternative to CsA treatment as it is immune-selective, and may be more effective at enabling wart formation in mice.</p>\",\"PeriodicalId\":18013,\"journal\":{\"name\":\"Laboratory Animals\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laboratory Animals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00236772231177857\",\"RegionNum\":4,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory Animals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00236772231177857","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

环孢素A (CsA)是一种免疫抑制药物,已广泛用于小鼠,剂量范围为10至200 mg/kg。我们小组在2016年进行了一项实验,我们通过灌胃给BALB/cJ小鼠75 mg/kg CsA (NeoralTM),使小鼠能够形成疣,并具有中等良好的耐受性。我们最近开始了另一项研究,在BALB/cJ小鼠中使用相同剂量和递送途径的CsA,以免疫抑制小鼠,使其对小鼠乳头瘤病毒感染易感。我们在这个病例报告中强调,与我们早期的研究相反,我们几乎立即观察到意想不到的毒性,并且在治疗五天后不得不终止最近的实验。7 ~ 8周龄BALB/cJ雌性小鼠每天灌胃CsA 75 mg/kg,连续5 d,因体重下降和小鼠死亡而停止治疗。在本研究中,CsA治疗后小鼠的存活率为80%,而我们2016年的研究为98%。小鼠表现出可能的急性肾损伤迹象,这在停用CsA后是可逆的。虽然目前尚不清楚为什么BALB/cJ小鼠对CsA的临床反应在两种实验中有显著差异,但本病例报告强调了CsA对小鼠健康的风险。在其他研究中,CD3消耗已被用于而不是CsA治疗,并且应被视为CsA治疗的替代方法,因为它具有免疫选择性,并且可能更有效地使小鼠形成疣。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Case report: An adverse response to cyclosporin A treatment in BALB/cJ mice.

Cyclosporin A (CsA) is an immunosuppressive drug that has been widely used in mice at a range of doses from 10 to 200 mg/kg. Our group carried out an experiment in 2016 where we delivered 75 mg/kg CsA (NeoralTM) to BALB/cJ mice by oral gavage to enable wart formation in mice, which was moderately well-tolerated. We recently commenced another study using the same dose and route of delivery of CsA in BALB/cJ mice in order to immune suppress mice to make them susceptible for mouse papillomavirus infection. We highlight in this case report that in contrast to our earlier study, we observed almost immediate unexpected toxicity and had to terminate the recent experiment after only five days of treatment. Seven to eight-week-old female BALB/cJ mice were treated with 75 mg/kg of CsA by oral gavage daily for five days before treatment was stopped due to body weight loss and mice becoming moribund. The probability of survival of the mice following CsA treatment was 80% in this study, compared with 98% in our 2016 study. Mice showed signs of probable acute kidney injury, which was reversible following withdrawal of CsA. Although it is unclear why the clinical response to CsA in BALB/cJ mice differed markedly between the two experiments, this case report highlights the risk of CsA to mouse welfare. CD3 depletion has been used rather than CsA treatment in other studies and should be considered as an alternative to CsA treatment as it is immune-selective, and may be more effective at enabling wart formation in mice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Laboratory Animals
Laboratory Animals 生物-动物学
CiteScore
4.90
自引率
8.30%
发文量
64
审稿时长
6-12 weeks
期刊介绍: The international journal of laboratory animal science and welfare, Laboratory Animals publishes peer-reviewed original papers and reviews on all aspects of the use of animals in biomedical research. The journal promotes improvements in the welfare or well-being of the animals used, it particularly focuses on research that reduces the number of animals used or which replaces animal models with in vitro alternatives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信